Zobrazeno 1 - 8
of 8
pro vyhledávání: '"35"'
Autor:
Montse Sanchez-Cespedes, Octavio A. Romero, Maria Saigi, Juan J. Alburquerque-Bejar, Eva Pros
Publikováno v:
Cancer Research. 80:998-998
Background The capability of tumors to avoid immune surveillance has emerged as therapeutically approachable, especially through the blockade of immune checkpoints (ICB) such as PD-L1/PD-1. We previously reported that B2M inactivating mutations in lu
Autor:
Hiroyuki Inoue, Yoichi Nakanishi, Hirono Tsutsumi, Yoshimasa Shiraishi, Koji Okamura, Isamu Okamoto
Publikováno v:
Cancer Research. 80:5596-5596
Immunogenic cell death characterized by the release of damage-associated molecular patterns (DAMPs) from dying cancer cells is a potential contributor to the synergistic antitumor effects of the combination of cytotoxic chemotherapy with immune check
Publikováno v:
Cancer Research. 79:2750-2750
DUBs are involved in tumorigenesis and are of high interest as potential targets for cancer therapy. However, target discovery is problematic due to the absence of clear DUB activity within subsets of human cancers. Our goal was to profile DUBs and t
Autor:
Pierre Laurent-Puig, Benoit Rousseau, Marco Alifano, Eric Pasmant, Audrey Briand, Diane Damotte, Dominique Vidaud, Aurélia Gruber, Ingrid Laurendeau, Nicolas Pécuchet, Benoit Terris, Ivan Bièche, Audrey Mansuet-Lupo, Michel Vidaud, Karen Leroy, Béatrice Parfait, Armelle Luscan, Hélène Blons, Jennifer Varin, Camille Tlemsani
Publikováno v:
Cancer Research. 78:5511-5511
Driver molecular alterations are found in >20% of non-small cell lung cancers (NSCLCs). They specifically target the RAS-MAPK pathway, including the EGFR, KRAS, and BRAF oncogenes. NF1 is a tumor suppressor gene that encodes neurofibromin, an inhibit
Publikováno v:
Cancer Research. 78:1566-1566
Therapies that target PD-1/PD-L1 and overcome checkpoint inhibition have shown great promise in the treatment of a variety of cancers, with PD-L1 expression demonstrated as a biomarker of therapy response in a variety of tumor types. There are multip
Autor:
Nobuhisa Ishikawa, Yataro Daigo, Kouki Inai, Hitoshi Nishimura, Nobuoki Kohno, Satoshi Hayama, Haruyasu Murakami, Eiju Tsuchiya, Yukio Takeshima, Yusuke Nakamura, Tatsuya Kato, Masaya Taniwaki, Atsushi Takano
Publikováno v:
Cancer Research. 65:9176-9184
Serum levels of amphiregulin and transforming growth factor-α (TGF-α), which were identified previously to be expressed at high levels in non–small cell lung cancer (NSCLC) with poor response to gefitinib, were examined by ELISA using blood sampl
Autor:
Vassilis Georgoulias, Eleni-Kyriaki Vetsika, Filippos Koinis, Athanasios Kotsakis, Despoina Aggouraki, Aristeidis Koukos, Zaharoula Lyristi, Despoina Kourougkiaouri, Galatea Kallergi
Publikováno v:
Cancer Research. 77:619-619
Background: Programmed cell death-1 (PD-1), an inhibitory immune check-point, plays a pivotal role in tumor immune escape. The interaction of PD-1 with its ligand (PD-L1) results in T cells exhaustion, and the blockade of this interaction can partial
Publikováno v:
Cancer Research. 70:3592-3592
Purpose: As the molecular target of irinotecan, TOP1 is a plausible predictive marker for irinotecan chemotherapy. Recently clinical studies have demonstrated that high TOP1 expression in cancer cells was predictive for benefit from irinotecan chemot